You are here

PARP inhibitors

GSK Pays $5.1B For Tesaro, Setting Up “PARP” Battle With Rival AstraZeneca

GSK Pays $5.1B For Tesaro, Setting Up “PARP” Battle With Rival AstraZeneca

Xconomy

PARP inhibitors

Flag link:

PARP makers search for a way to break through

PARP makers search for a way to break through

Biopharma Dive

Clovis Oncology

PARP inhibitors

Flag link:

PARPs may be crushing it in the clinic, but half of doctors are still wary: executive

PARPs may be crushing it in the clinic, but half of doctors are still wary: executive

Fierce Pharma

PARP inhibitors

Clovis Oncology

Flag link:

Mammoth Lynparza survival win puts AZ, Merck in line for $1B launch

Mammoth Lynparza survival win puts AZ, Merck in line for $1B launch

Fierce Pharma

PARP inhibitors

BRCA-mutated ovarian cancer

Flag link:

Can Pfizer's new breast cancer drug Talzenna really make a dent in the PARP field?

Can Pfizer's new breast cancer drug Talzenna really make a dent in the PARP field?

Fierce Pharma

PARP inhibitors

Flag link:

FDA approves Pfizer's drug for advanced breast cancer

FDA approves Pfizer's drug for advanced breast cancer

Reuters

PARP inhibitors

BRCA-mutant breast cancer

Flag link:

PARP inhibitors show promise for treating ALS and other brain disorders

PARP inhibitors show promise for treating ALS and other brain disorders

Fierce Biotech

PARP inhibitors

Flag link:

Lilly Asian Ventures backs Impact’s PARP research again, chipping in for $30M Series C led by Decheng Capital

Lilly Asian Ventures backs Impact’s PARP research again, chipping in for $30M Series C led by Decheng Capital

Endpoints

PARP inhibitors

Lilly Asian Ventures

Flag link:

AstraZeneca Goes Up Against 2 Cancer Upstarts

AstraZeneca Goes Up Against 2 Cancer Upstarts

Motley Fool

Clovis Oncology

PARP inhibitors

Flag link:

In wake of Tecentriq bladder cancer bust and lost market share, Roche tries Tesaro combo

In wake of Tecentriq bladder cancer bust and lost market share, Roche tries Tesaro combo

Fierce Pharma

PARP inhibitors

Flag link:

In a pioneering first, AstraZeneca scores FDA OK to use its PARP against breast cancer

In a pioneering first, AstraZeneca scores FDA OK to use its PARP against breast cancer

Endpoints

PARP inhibitors

metastatic breast cancer

Flag link:

A New PARP Drug For Breast Cancer

A New PARP Drug For Breast Cancer

Forbes

PARP inhibitors

metastatic breast cancer

Flag link:

In a showdown with AstraZeneca, Pfizer posts solid — and very familiar — PhIII breast cancer data for talazoparib

In a showdown with AstraZeneca, Pfizer posts solid — and very familiar — PhIII breast cancer data for talazoparib

Endpoints

advanced breast cancer

PARP inhibitors

Flag link:

AstraZeneca, Merck, Clovis and Tesaro, all vying for share, may all win on faster PARP growth

AstraZeneca, Merck, Clovis and Tesaro, all vying for share, may all win on faster PARP growth

Fierce Pharma

Clovis Oncology

PARP inhibitors

Flag link:

Clovis looks to expand label for PARP inhibitor

Clovis looks to expand label for PARP inhibitor

Biopharma Dive

Clovis Oncology

PARP inhibitors

Flag link:

AstraZeneca, Tesaro and Clovis need to slash the cost of PARP meds, watchdog says

AstraZeneca, Tesaro and Clovis need to slash the cost of PARP meds, watchdog says

Fierce Pharma

Clovis Oncology

PARP inhibitors

Flag link:

A Pill Might Control Pancreatic Cancer, Even If It Doesn't Cure It

A Pill Might Control Pancreatic Cancer, Even If It Doesn't Cure It

Forbes

pancreatic cancer

PARP inhibitors

Clovis Oncology

Flag link:

Tesaro's Zejula rolls to No. 1 PARP position with big Q2

Tesaro's Zejula rolls to No. 1 PARP position with big Q2

Fierce Pharma

PARP inhibitors

Flag link:

Cancer-fighting PARP drugs from AstraZeneca, Clovis and Tesaro largely overpriced, watchdog says

Cancer-fighting PARP drugs from AstraZeneca, Clovis and Tesaro largely overpriced, watchdog says

Fierce Pharma

PARP inhibitors

Clovis Oncology

Flag link:

Upstart women’s oncology company in-licenses PhII PARP; Beijing biotech grabs $29M startup round

Upstart women’s oncology company in-licenses PhII PARP; Beijing biotech grabs $29M startup round

Endpoints

PARP inhibitors

Jazz Pharmaceuticals

Flag link:

Pages